Research Article

Identification of the Hub Genes and Potential Regulation Network in Chronic Hepatitis B via Bioinformatics Analysis

Jingjing Fan,1 Yong Chen,1 Wei Zhang,2 Xiaoying Zhou,1 Xue Bai,1 Caifang Chang,1 Yongping Han,1 and Jinlu Liu2

1Department of Infectious Diseases, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000 Hebei, China
2Department of Microbiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000 Hebei, China

Correspondence should be addressed to Jingjing Fan; fanjingjing@hbbfyfy.com.cn

Received 30 June 2022; Revised 19 August 2022; Accepted 29 August 2022; Published 23 September 2022

Academic Editor: Jun Yang

Copyright © 2022 Jingjing Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Chronic hepatitis B (CHB) is a serious infectious disease which is induced by hepatitis B virus (HBV) infection. This project was conducted to reveal the potential mechanism in CHB development via analyzing the public clinical data. Methods. GSE33857 and GSE110217, obtained from the GEO database, were used for bioinformatics excavation. Briefly, the raw data of GSE33857 and GSE110217 were analyzed with the GEO2R, and then the expressed matrix files were generated. The matrix files was visualized as heat map with R software. The targets of the miRNAs were analyzed with the miRDIP database. The functional annotation and pathway enrichment were performed using “clusterProfiler” package in R software. The STRING database was utilized to analyze the interaction of the DEGs, and the PPI and miRNA-mRNA network were established according to the related results. Results. 93 downregulated genes and 17 upregulated genes in GES33857, and 111 downregulated and 40 upregulated genes in GSE110217 were identified as the hub nodes. The targets of the DEGs in the datasets were enriched in PI3K/AKT and MAPK pathways and associated with transcriptional regulation. Moreover, PPI and miRNA-mRNA networks were also established with the DEGs and related targets in the datasets. miR-122-5p, miR-125b-5p, miR-136-5p, miR-194-5p, miR-139-5p, miR-140-5p, miR-181a-5p, and miR-29b-3p were identified as the potential biomarkers in CHB. Conclusion. Eight miRNAs, including miR-122-5p, miR-125b-5p, miR-136-5p, miR-194-5p, miR-139-5p, miR-140-5p, miR-181a-5p, and miR-29b-3p, were identified as the potential biomarkers in CHB, and the PPI and miRNA-mRNA networks were also established.

1. Introduction

Chronic hepatitis B (CHB) is an intractable malignant infectious disease which has high incidence in the whole world [1, 2]. At present, there are few ways to completely heal this disease. The infection of chronic hepatitis B virus is the direct factor inducing the formation and development of major patients with CHB, while some virus carriers also exhibit normal clinical indexes as well as healthy people [3]. Over the decade, increasing patients have been diagnosed with CHB year by year. HBV infections has been generally recognized as the critical reason inducing the liver-related diseases [4]. Statistically, since 1998, almost 250 million people have been confirmed to infect the CHB virus [5]. The patients with CHB may develop to various poor outcomes. At present, some antiviral drugs can impede the progression of CHB virus-induced complications, while they could not remove the persistent damage of the virus on patients in a long term [6].

Abundant research has reported that the patients with CHB generally exhibited remarkably difference in gene profile compared with healthy persons [7, 8]. miRNAs serve as critical roles in cellular activities, and the disorder of miRNA profile is also direct reason leading the formation and deterioration of the diseases [9]. For CHB, considerable reports have indicated the pathological tissues of the
Change

- Down
- Not
- Up

Figure 1: Continued.
patients generally exhibit obvious difference in miRNA profiles [10]. With the application of HTS analysis methods, accumulating miRNAs have been investigated and successfully applied for clinical diagnosis and treatment [11]. The excavation of public data may be a promising way to reveal the potential mechanism in CHB development. Increasing researches try to illustrate the profile change in CHB development [12]. Some genes may have great potential for clinical application.

This research was conducted to analyze the potential mechanism of CHB progression via bioinformatics analysis and construct the miRNA-mRNA network to provide some reference for CHB treatment.

2. Materials and Methods

2.1. Data Source. The datasets including GSE33857 (GPL10656) and GSE110217 (GPL15018) were originated from the GEO database, and the related matrix files of the datasets were obtained via GEO2R analysis. For GSE33857, 12 normal liver tissues and 4 CHB tissues were selected as the subjects. For GSE110217, 4 normal liver tissues and 16 non-HCC CHB tissues were selected as the subjects.

2.2. Identification of DEGs. The matrix files of GES and GES were obtained to screen the DEGs. In brief, the genes with \(|\log_{2} FC| \geq 2\) and \(p\) value < 0.05 were selected as the DEGs for next analysis. The volcano map and heat map of the DEGs were figured with R language.

2.3. Enrichment Analysis. To obtain the related functional annotation and enrichment results of the DEGs, the DEGs or the related targets (for miRNAs) were analyzed using “clusterProfiler” package in R software [13, 14]. The related GO annotation of the DEGs was obtained for GO enrichment, and the related results of the genes in cellular component (CC), biological process (BP), and molecular function (MF) were obtained. The enrichment results were visualized with R language.

2.4. Networks Establishment and Modular Analysis. The DEGs or the related targets (for miRNAs) were analyzed with the STRING database to establish the interactions of the DEGs. Moreover, the combined score more than 0.4 was considered as statistical meaning. For modular analysis, the results obtained from STRING were analyzed with the plug-in unit of Cytoscape (MCODE). The mirDIP was utilized to predict target mRNA of miRNAs. For miRNA-mRNA network establishment, the miRNAs and the target mRNAs in GES were constructed with the Cytoscape.
Transcriptional misregulation in cancer
TGF-beta signaling pathway
RNA degradation
Renal cell carcinoma
Relaxin signaling pathway
Proteoglycans in cancer
Protein digestion and absorption
PI3K-Akt signaling pathway
Phosphatidylinositol signaling system
Pathway in cancer
Mucin type O-glycan biosynthesis
mTOR signaling pathway
MAPK signaling pathway
Hepatocellular carcinoma
Gastric cancer
FoxO signaling pathway
Endocytosis
EGFR tyrosine kinase inhibitor resistance
Colorectal cancer
Cellular senescence

Figure 2: Continued.
| Disease Markers |
|----------------|
| Small cell lung cancer |
| Signaling pathways regulating pluripotency of stem cells |
| Salmonella infection |
| Relaxin signaling pathway |
| Proteoglycans in cancer |
| Protein digestion and absorption |
| Prostate cancer |
| Prolactin signaling pathway |
| PI3K-Akt signaling pathway |
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
| Pathways in cancer |
| p53 signaling pathway |
| Non-small cell lung cancer |
| Neurotrophin signaling pathway |
| mTOR signaling pathway |
| MicroRNAs in cancer |
| Melanoma |
| Measles |
| MAPK signaling pathway |
| Lipid and atherosclerosis |
| Kaposi sarcoma-associated herpesvirus infection |
| Human T-cell leukemia virus 1 infection |
| Human papillomavirus infection |
| Human immunodeficiency virus 1 infection |
| Hepatocellular carcinoma |
| Hepatitis C |
| Hepatitis B |
| Hedgehog signaling pathway |
| GnRH signaling pathway |
| Glioma |
| Gastric cancer |
| FoxO signaling pathway |
| Focal adhesion |
| Fc epsilon RI signaling pathway |
| ErbB signaling pathway |
| Epstein-Barr virus infection |
| Endometrial cancer |
| Endocrine resistance |
| EGFR tyrosine kinase inhibitor resistance |
| Colorectal cancer |
| Chronic myeloid leukemia |
| Chemical carcinogenesis-receptor activation |
| Chagas disease |
| Cellular senescence |
| Cell cycle |
| Breast cancer |
| Bladder cancer |
| Autophagy-animal |
| AGE-RAGE signaling pathway in diabetic complications |
| Acute myeloid leukemia |

**Figure 2:** Continued.
3. Results

3.1. Identification of the DEGs. The GSE33857 and GSE110217 were analyzed with the GEO2R to identify the DEGs in the progression of CHB. In the results, 93 downregulated genes and 17 upregulated genes were found in the GSE33857, and 111 downregulated and 40 upregulated genes were found in the GSE110217 (Figures 1(a) and 1(b)). The top 10 upregulated and top 10 downregulated DEGs were visualized with heat maps (Figures 1(c) and 1(d)).

3.2. KEGG Enrichment Analysis. To reveal the potential pathological mechanism of CHB, the targets of the DEGs were analyzed with the DAVID database. The results showed that 26 common genes were found in GSE33857 and GSE110217 (Figure 2(a)). The targets of the DEGs in GSE33857 were mainly enriched in PI3K/AKT and MAPK pathways, and the genes including SMAD2, FZD3, SMARCD2, PTEN, GAB1, TGFA, ARID1A, ARID2, MET, SOS2, TGFBR2, and NFE2L2 were related with the hepatocellular carcinoma related pathway (Figure 2(b)). For GSE110217, the targets of the DEGs were also enriched in PI3K/AKT and MAPK pathways, and the genes including NRAS, CCND1, AKT3, PTEN, E2F1, AXIN2, SOS2, TGFBR1, and LRP6 were enriched in hepatocellular carcinoma related pathway (Figure 2(c)). Moreover, the common targets of the DEGs in GSE33857 and GSE110217 were majorly associated with the cancer development pathways including pathways in cancer, microRNA in cancer, and transcriptional in cancer (Figure 2(d)).

3.3. Functional Analysis. To reveal the molecular functions of the DEGs in CHB development, the targets of the DEGs in GSE33857 and GSE110217 were used for GO enrichment analysis. The results showed that the targets of the DEGs in GSE33857 and GSE110217 were located in nucleus, cytosol, nucleoplasm, and so on and were associated with the regulation of RNA transcription. Moreover, the molecular functions of these genes were related with the binding of protein, metal ion, the promoter DNA sequence, and so on (Figure 3).
Figure 3: Continued.
3.4. Network Establishment. To reveal the potential molecular interaction relationship, the targets of the DEGs in GSE33857 and GSE110217 were analyzed with the STRING database. Moreover, the top 500 genes were used to establish the PPI network and miRNA-mRNA network.

The results showed that 3 clusters were screened in both GSE33857 and GSE110217 via MCODE plug-in unit. For GSE33857, the targets of DEGs including PTEN, HIF1, VEGFA, SMAD2, PPARG, and ESR1 were identified as the hub nodes (Figures 4(a)–4(c)). ESR1, FBXW7, NRAS, PTEN, CCND1, and BTRC were identified as the hub nodes in GSE110217 (Figures 4(d)–4(f)). For common targets VEGFA, ESR1, DNMT1, KMT2A, and KAT2B were identified as hub nodes (Figures 4(g)–4(i)). Moreover, the miRNA-mRNA network was also established based on the targets of common DEGs in GSE33857 and GSE110217, and the results showed that 15 miRNA nodes and 351 mRNA nodes were included in the network (Figure 5).

4. Discussion

Chronic hepatitis B (CHB) is still a malignant infectious disease which seriously threatens the health of human and provides great challenge for the modern medical system [15]. In this research, the bioinformatics analysis was applied to investigate the potential regulation mechanism in the progression of CHB, and the GSE33857 and GSE110217 were used to investigate the potential biomarkers.

miRNAs have been confirmed as critical roles in regulating the normal progression of cells, and miRNA dysfunction has been proved as a direct reason leading the malignant progression of multiple diseases [16]. This investigation also discovered that the miRNA profile in the patient’s tissues exhibited significant difference compared with that in the normal subjects [17]. 15 miRNAs were selected as the hub nodes in CHB. The research has confirmed that reduced miR-122-5p is closely related with the progression of HBV-induced liver fibrosis, and miR-122-5p can effectively impede the deterioration of the symptom via targeting IL7R [18]. Increased miR-125b-5p has been identified as a serum biomarker for HBV infection by several reporters [19]. Deng et al. has also confirmed that miR-125b-5p can interact with LIN28B to induce the posttranscriptional regulation of HBV [20]. He et al. have indicated that decreased miR-136-5p can aggravate the liver cancer development induced by HBV [21]. miR-139-5p has been found to block the malignant behaviors of hepatocellular carcinoma cells [23]. miR-140-5p has also been confirmed to impede the EMT process via targeting TGFBR1 [24]. miR-181a-5p inhibited the cellular malignant proliferation via repressing EGR1 in hepatocellular carcinoma [25]. Zhou et al. have indicated that miR-29b-3p can impede the metastasis of hepatocellular carcinoma via blocking DNMT3A [26].

miRNA is characterized with repressing the translation via binding with the 3'-UTR of the proteins. In this research,
the targets of the miRNAs have been screened by miRDIP targets. PTEN, HIF1, VEGFA, SMAD2, PPARG, and ESR1 were identified as the hub nodes in GSE3857. ESR1, FBXW7, NRAS, PTEN, CCND1, and BTRC were identified as the hub nodes in GSE110217. VEGFA, ESR1, DNMT1, KMT2A, and KAT2B were identified as hub nodes in common targets of GSE3857 and GSE110217. DNMT1 has been identified as a serum biomarker event in cancer development, and DNMT1 has been also confirmed to be associated with HBV-related liver cancer [27]. In this research, DNMT1 was identified as the target of miR-148a-3p. FBXW7 plays a tumor supporter role in multiple tumors, and increased FBXW7 has been confirmed to be closely related with resistance of liver cancer cells on sorafenib [28]. This research found that FBXW7 served as a target of miR-27b-3p, and miR-27b-3p was dramatically reduced in HBV-infected tissues. Neovascularization is a biomarker event in the progression of some tumors. For gaining more nutrient, the tumor focuses generally exhibit aberrant angiopoiesis. VEGFA serves as critical role in driving the process of angiopoiesis in local low oxygen environment, which has been also identified as the biomarker in cancer development. Increased VEGFA is associated with liver cancer development, and several reports have indicated that VEGFA inhibition can extremely block the malignant behaviors of the cancer cells [29]. Moreover, increased VEGFA has been observed in HBV-related liver cancer.

Abundant reports have confirmed that HBV infection can induce the aberrant activities of the pathways in liver cells. This research has indicated that the DEGs in GSE33857 and GSE110217 were enriched in PI3K/AKT and MAPK pathways. PI3K/Akt signaling pathway is an important signal transduction pathway in cells, which plays an important role in inhibiting apoptosis and promoting cell survival and proliferation. Akt is an important downstream target kinase in PI3K signal transduction pathway, which has silk threonine kinase activity. When cells are stimulated by extracellular signals, PI3K activation generates PIP3 to translocate Akt to the cell membrane and localize near PDK1 and PDK2. The conformation of Akt changes,
exposing its phosphorylation site. Subsequently, Akt activation further acts on its downstream molecules, thus participating in cell growth, development, differentiation, and proliferation. The abnormal activation of PI3K/AKT pathways is related with the aberrant proliferation and enhanced invasive ability of tumor cells. HBV has been confirmed to induce the antiapoptosis ability of liver cancer cells via activating the PI3K/AKT pathway [29]. Moreover, MAPK pathway dysfunction could drive the deterioration of HBV-mediated liver cancer via promoting the transcription of surface protein hPIAS1 of HBV [30].

In conclusion, eight miRNAs, including miR-122-5p, miR-125b-5p, miR-136-5p, miR-194-5p, miR-139-5p, miR-140-5p, miR-181a-5p, and miR-29b-3p, were identified as the potential biomarkers in CHB, and the PPI and miRNA-mRNA networks were also established. The limitations of this study lie in the use of too few data sets and the lack of experimental validation. The next study should further verify the effect of these candidate biomarkers on CHB in vivo and in vitro.

Data Availability

Data to support the findings of this study is available on reasonable request from the corresponding author.

Conflicts of Interest

The authors do not have conflicts of interest to declare.

Acknowledgments

This research was funded by the 2018 Hebei Medical Science Research Key Project Plan (analysis of HBV genome sequence and molecular characteristics in patients with chronic hepatitis B in Zhangjiakou, Hebei Province), grant number 20180827.

References

[1] K. S. Liem, S. Fung, D. K. Wong et al., “Limited sustained response after stopping nucleos(t)ide analogues in patients
with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study),” Gut, vol. 68, no. 12, pp. 2206–2213, 2019.

[2] T. C. Tseng, C. Y. Peng, Y. C. Hsu et al., “Baseline mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy,” Liver Cancer, vol. 9, no. 2, pp. 207–220, 2020.

[3] D. Qiao, Y. Chen, and L. Liu, “Engineered therapeutic nanovaccine against chronic hepatitis B virus infection,” Biomaterials, vol. 269, p. 120674, 2021.

[4] J. Ahn, J. K. Lim, H. M. Lee et al., “Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results from the ENUMERATE study,” The American Journal of Gastroenterology, vol. 111, no. 9, pp. 1297–1304, 2016.

[5] S. Tran, D. Jeong, L. Henry, R. C. Cheung, and M. H. Nguyen, “Initial evaluation, long-term monitoring, and hepatocellular carcinoma surveillance of chronic hepatitis B in routine practice: a nationwide US study,” The American Journal of Gastroenterology, vol. 116, no. 9, pp. 1885–1895, 2021.

[6] Y. E. Chon, J. Y. Park, S. M. Myoung et al., “Improvement of liver fibrosis after long-term antiviral therapy assessed by Fibroscan in chronic hepatitis B patients with advanced fibrosis,” The American Journal of Gastroenterology, vol. 112, no. 6, pp. 882–891, 2017.

[7] H. Wakasugi, H. Takahashi, T. Ninuma et al., “Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment,” Cancer Letters, vol. 434, pp. 91–100, 2018.

[8] Y. Ouyang, Y. Tang, L. Fu et al., “Exosomes secreted by chronic hepatitis B patients with PNALT and liver inflammation grade ≥ A2 promoted the progression of liver cancer by transferring miR-25-3p to inhibit the co-expression of TGF21 and HHIP,” Cell Proliferation, vol. 53, no. 7, article e12833, 2020.

[9] W. Gan, X. Chen, Z. Wu et al., “The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment,” Annals of Translational Medicine, vol. 10, no. 10, p. 536, 2022.

[10] Y. Mao, X. Wang, W. Hu et al., “Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs,” Antiviral Research, vol. 204, p. 105366, 2022.

[11] V. V. Loukachov, K. A. van Dort, I. Maurer et al., “Identification of liver and plasma microRNAs in chronic hepatitis B virus infection,” Frontiers in Cellular and Infection Microbiology, vol. 12, p. 790964, 2022.

[12] G. Ning, L. M. Zhen, W. X. Xu et al., “Suppression of complement component 2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients,” Journal of Viral Hepatitis, vol. 27, no. 10, pp. 1071–1081, 2020.

[13] T. Wu, E. Hu, S. Xu et al., “clusterProfiler 4.0: a universal enrichment tool for interpreting omics data,” Innovation, vol. 2, no. 3, article 100141, 2021.

[14] C. Gu, J. Chen, X. Deng et al., “Hippo pathway core genes based prognostic signature and immune infiltration patterns in lung squamous cell carcinoma,” Frontiers in Oncology, vol. 11, p. 680918, 2021.

[15] B. Chen, W. Wang, W. Xu, L. Ying, C. Zhou, and M. Zheng, “Serum free light chain is associated with histological activity and cirrhosis in patients with chronic hepatitis B,” International Immunopharmacology, vol. 99, p. 107881, 2021.

[16] Q. Chu, J. Li, J. Chen, and Z. Yuan, “HBV induced the discharge of intrinsic antiviral miRNAs in HBV-replicating hepatocytes via extracellular vesicles to facilitate its replication,” Journal of General Virology, vol. 103, no. 5, 2022.

[17] J. Zhao, X. C. Zhu, X. S. Wu et al., “Identification of miR-4644 as a suitable endogenous normalizer for circulating miRNA quantification in hepatocellular carcinoma,” Journal of Cancer, vol. 11, no. 23, pp. 7032–7044, 2020.

[18] B. Li, Y. Li, S. Li, H. Li, L. Liu, and H. Yu, “Circ_MTM1 knockdown inhibits the progression of HBV-related liver fibrosis via regulating IL7R expression through targeting miR-122-5p,” American Journal of Translational Research, vol. 14, no. 4, pp. 2199–2211, 2022.

[19] M. Ninomiya, Y. Kondo, O. Kimura et al., “The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen,” Journal of Viral Hepatitis, vol. 23, no. 5, pp. 330–339, 2016.

[20] W. Deng, X. Zhang, Z. Ma, Y. Lin, and M. Lu, “MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let‐7 axis,” RNA Biology, vol. 14, no. 10, pp. 1389–1398, 2017.

[21] W. He, X. Zhu, X. Tang, X. Xiang, J. Yu, and H. Sun, “Circ_0027089 regulates NACC1 by targeting miR-136-5p to aggravate the development of hepatitis B virus-related hepatocellular carcinoma,” Anti-Cancer Drugs, vol. 33, no. 1, pp. e336–e348, 2022.

[22] K. O. Nielsen, K. S. Jacobsen, A. H. Mirza et al., “Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model,” Experimental Cell Research, vol. 371, no. 1, pp. 92–103, 2018.

[23] S. Hua, L. Lei, L. Deng et al., “miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1,” Oncogene, vol. 37, no. 12, pp. 1624–1636, 2018.

[24] Y. H. Tang, G. L. He, S. Z. Huang et al., “The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma,” Molecular Oncology, vol. 13, no. 5, pp. 1296–1310, 2019.

[25] J. G. Bi, J. F. Zheng, Q. Li et al., “MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma,” The International Journal of Biochemistry & Cell Biology, vol. 106, pp. 107–116, 2019.

[26] Y. Zhou, K. Li, T. Dai et al., “Long non-coding RNA HCP5 functions as a sponge of miR-29b-3p and promotes cell growth and metastasis in hepatocellular carcinoma through upregulating DNMT3A,” Aging (Albany NY), vol. 13, no. 12, pp. 16267–16286, 2021.

[27] Y. Deng, J. Wang, M. Huang, G. Xu, W. Wei, and H. Qin, “Inhibition of miR-148a-3p resists hepatocellular carcinoma progression of hepatitis C virus infection through suppressing c-Jun and MAPK pathway,” Journal of Cellular and Molecular Medicine, vol. 23, no. 2, pp. 1415–1426, 2019.

[28] X. Feng, B. Zou, T. Nan et al., “MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7,” International Journal of Medical Sciences, vol. 19, no. 2, pp. 257–266, 2022.
[29] Y. Chen, X. Bai, Q. Zhang et al., “The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway,” *Cancer Letters*, vol. 380, no. 1, pp. 98–105, 2016.

[30] H. Wang, D. Wu, X. Wang et al., “Hepatitis B virus surface protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways,” *Biological Chemistry*, vol. 397, no. 11, pp. 1173–1185, 2016.